Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONSFree Report) by 2.6% during the 4th quarter, HoldingsChannel reports. The firm owned 191,893 shares of the company’s stock after selling 5,049 shares during the quarter. Rhumbline Advisers’ holdings in Ionis Pharmaceuticals were worth $6,709,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Ionis Pharmaceuticals by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after buying an additional 183,814 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock valued at $57,807,000 after acquiring an additional 114,914 shares in the last quarter. ARK Investment Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 1.7% in the third quarter. ARK Investment Management LLC now owns 1,384,269 shares of the company’s stock valued at $55,454,000 after acquiring an additional 23,244 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of Ionis Pharmaceuticals by 3.5% during the third quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company’s stock valued at $53,376,000 after acquiring an additional 45,300 shares during the period. Finally, Groupama Asset Managment raised its holdings in Ionis Pharmaceuticals by 4.1% during the third quarter. Groupama Asset Managment now owns 916,060 shares of the company’s stock worth $367,000 after purchasing an additional 36,084 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Transactions at Ionis Pharmaceuticals

In related news, Director Michael R. Hayden acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $36.22 per share, for a total transaction of $181,100.00. Following the completion of the acquisition, the director now directly owns 35,219 shares in the company, valued at approximately $1,275,632.18. The trade was a 16.55 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 38,843 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $31.65, for a total value of $1,229,380.95. Following the transaction, the chief executive officer now directly owns 180,683 shares of the company’s stock, valued at $5,718,616.95. This represents a 17.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,816 shares of company stock valued at $3,603,914 over the last three months. 2.71% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IONS. Piper Sandler decreased their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. StockNews.com cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Finally, BMO Capital Markets lowered their price objective on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a research note on Thursday, February 20th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Read Our Latest Research Report on Ionis Pharmaceuticals

Ionis Pharmaceuticals Stock Performance

NASDAQ IONS opened at $31.76 on Thursday. The company’s fifty day moving average is $33.32 and its two-hundred day moving average is $37.98. The firm has a market capitalization of $5.05 billion, a price-to-earnings ratio of -10.45 and a beta of 0.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82. Ionis Pharmaceuticals, Inc. has a 52-week low of $30.23 and a 52-week high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONSGet Free Report) last posted its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. During the same quarter in the prior year, the firm earned $0.12 EPS. The firm’s quarterly revenue was down 30.2% compared to the same quarter last year. Equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

About Ionis Pharmaceuticals

(Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Featured Articles

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONSFree Report).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.